Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHL1101 vs MabThera in RA
NCT03161457Phase 1Terminated
- Sponsor
- Eden Biologics, Inc.
- Start
- Feb 2017
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, randomised, double-blind trial of rituximab biosimilar JHL1101 in rheumatoid arthritis (RA) (2 arms), sponsored by Eden Biologics, Inc. Primary endpoints: Area under plasma concentration versus time curve, Trough Concentration at Day 15 and 1 more. Started Feb 2017; status: terminated.
02
Drugs
rituximab biosimilar JHL1101
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03161457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161457.